Wockhardt Limited
Wockhardt Limited Fundamental Analysis
Wockhardt Limited (WOCKPHARMA.NS) shows weak financial fundamentals with a PE ratio of 124.76, profit margin of 6.31%, and ROE of 4.60%. The company generates $33.8B in annual revenue with moderate year-over-year growth of 7.24%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 51.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze WOCKPHARMA.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakWOCKPHARMA.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateWOCKPHARMA.NS shows balanced valuation metrics.
Growth Score
ExcellentWOCKPHARMA.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentWOCKPHARMA.NS maintains a strong and stable balance sheet.
Profitability Score
WeakWOCKPHARMA.NS struggles to sustain strong margins.
Key Financial Metrics
Is WOCKPHARMA.NS Expensive or Cheap?
P/E Ratio
WOCKPHARMA.NS trades at 124.76 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, WOCKPHARMA.NS's PEG of -0.05 indicates potential undervaluation.
Price to Book
The market values Wockhardt Limited at 5.38 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 36.69 times EBITDA. This signals the market has high growth expectations.
How Well Does WOCKPHARMA.NS Make Money?
Net Profit Margin
For every $100 in sales, Wockhardt Limited keeps $6.31 as profit after all expenses.
Operating Margin
Core operations generate 19.60 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.60 in profit for every $100 of shareholder equity.
ROA
Wockhardt Limited generates $2.47 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Wockhardt Limited generates limited operating cash flow of $1.89B, signaling weaker underlying cash strength.
Free Cash Flow
Wockhardt Limited produces free cash flow of $1.19B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $7.33 in free cash annually.
FCF Yield
WOCKPHARMA.NS converts 0.45% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
124.76
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.38
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.89
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.45
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.61
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How WOCKPHARMA.NS Stacks Against Its Sector Peers
| Metric | WOCKPHARMA.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 124.76 | 29.06 | Worse (Expensive) |
| ROE | 4.60% | 733.00% | Weak |
| Net Margin | 6.31% | -53111.00% (disorted) | Weak |
| Debt/Equity | 0.45 | 0.38 | Neutral |
| Current Ratio | 1.61 | 4.02 | Neutral |
| ROA | 2.47% | -19397.00% (disorted) | Weak |
WOCKPHARMA.NS outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Wockhardt Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-17.61%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
47.58%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-102.62%
Industry Style: Defensive, Growth, Innovation
Declining